Genmab — Oktober 2020
-
På lang sigt skal aktien up up and away. Pga epco, GEN1046, Amivantamab, Kesimpta. Genmab går fra at være en one trick pony, til et multiblockbuster biotech selskab
-
Specielt epco og GEN1046 er ekstremt vigtige da Genmabs ejerandel er 50%
-
Agree
-
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer https://clinicaltrials.gov/ct2/show/NCT04599712
-
The Phase 1 Talquetamab trial changed into a Phase 1/Phase 2 and increases enrollment from 185 to 245 https://clinicaltrials.gov/ct2/history/NCT03399799?A=20&B=21&C=merged#StudyPageTop
-
Stoxx: Europæiske health care aktier i plus i stærk negativt
markedhttps://www.proinvestor.com/investornyt/668982/stoxx-europaeiske-health-care-aktier-i-plus-i-staerk-negativt-marked -
Ses vi til øl i aften? https://event.webinarjam.com/register/5/qro52t7
-
God morgen.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind